Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -15.40% is 65% above its 2-year average of -44.33%, near the high end of its 2-year range (-100.23%–-15.40%).
As of the fiscal period ended Tuesday, June 30, 2026. 8.68% above its 12-month average of -16.86%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -15.40%.
RETURN ON EQUITY (ROE)
-15.40%
RETURN ON EQUITY (ROE) AVG TTM
-16.86%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+8.68%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.21%
median of 655 covered companies
CURRENT VS SECTOR MEDIAN
+61.70%
vs the sector median at left
Market Cap
$5.95B
Return on Equity (ROE)
20.38%
TTM Avg
5.87%
3Y Avg
3.40%
5Y Avg
3.36%
Market Cap
$5.90B
Return on Equity (ROE)
-39.33%
TTM Avg
-54.18%
3Y Avg
-65.89%
5Y Avg
-59.69%
Market Cap
$5.74B
Return on Equity (ROE)
12.33%
TTM Avg
0.28%
3Y Avg
12.51%
5Y Avg
-14.51%
Market Cap
$5.68B
Return on Equity (ROE)
-21.80%
TTM Avg
-16.70%
3Y Avg
-22.00%
5Y Avg
-23.98%
Market Cap
$6.33B
Return on Equity (ROE)
-94.50%
TTM Avg
-115.58%
3Y Avg
-102.12%
5Y Avg
-85.25%
Market Cap
$5.54B
Return on Equity (ROE)
-9.09%
TTM Avg
-8.34%
3Y Avg
-4.98%
5Y Avg
-4.98%
Market Cap
$5.52B
Return on Equity (ROE)
-1.93%
TTM Avg
-0.70%
3Y Avg
0.57%
5Y Avg
0.69%
Market Cap
$6.51B
Return on Equity (ROE)
20.99%
TTM Avg
25.07%
3Y Avg
24.12%
5Y Avg
13.08%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRAIL Inc. (GRAL) | $6.01B | -15.40% | -16.86% | N/A | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 20.38% | 5.87% | 3.40% | 3.36% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.90B | -39.33% | -54.18% | -65.89% | -59.69% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.74B | 12.33% | 0.28% | 12.51% | -14.51% |
| CG Oncology Inc. (CGON)vs › | $5.68B | -21.80% | -16.70% | -22.00% | -23.98% |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.33B | -94.50% | -115.58% | -102.12% | -85.25% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.54B | -9.09% | -8.34% | -4.98% | -4.98% |
| RadNet, Inc. (RDNT)vs › | $5.52B | -1.93% | -0.70% | 0.57% | 0.69% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 20.99% | 25.07% | 24.12% | 13.08% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.52B | 476.51% | 2.59% | -115.75% | -71.67% |
ROE
-15.4%
ROA
-13.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -15.40% |
| 2026-03-31 | -15.81% |
| 2025-12-31 | -15.84% |
| 2025-09-30 | -18.14% |
| 2025-06-30 | -19.14% |
| 2025-03-31 | -79.31% |
| 2024-12-31 | -80.97% |
| 2024-09-30 | -74.80% |
| 2024-06-30 | -100.23% |
| 2024-03-31 | -32.80% |
| 2023-12-31 | -35.21% |
